These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9213165)

  • 21. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin agonists for treatment of acromegaly.
    Ben-Shlomo A; Melmed S
    Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Octreotide long-acting repeatable for acromegaly.
    Cozzi R; Attanasio R
    Expert Rev Clin Pharmacol; 2012 Mar; 5(2):125-43. PubMed ID: 22390555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide for acromegaly treatment: a reappraisal.
    Giustina A; Karamouzis I; Patelli I; Mazziotti G
    Expert Opin Pharmacother; 2013 Dec; 14(17):2433-47. PubMed ID: 24124691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
    Frohman LA; Bonert V
    Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acromegaly and pharmacotherapy].
    Krsek M
    Vnitr Lek; 2015 Feb; 61(2):95-6. PubMed ID: 25989633
    [No Abstract]   [Full Text] [Related]  

  • 28. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
    J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression.
    Kasuki L; Vieira Neto L; Wildemberg LE; Colli LM; de Castro M; Takiya CM; Gadelha MR
    Endocr Relat Cancer; 2012 Jun; 19(3):L25-9. PubMed ID: 22420004
    [No Abstract]   [Full Text] [Related]  

  • 30. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly.
    Biermasz NR; Pereira AM; Frölich M; Romijn JA; Veldhuis JD; Roelfsema F
    Am J Physiol Endocrinol Metab; 2004 Jan; 286(1):E25-30. PubMed ID: 14506078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients.
    Evran M; Sert M; Tetiker T
    BMC Endocr Disord; 2014 Dec; 14():97. PubMed ID: 25511633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The predictive value of the IGF-1 level in acromegaly patients treated by surgery and a somatostatin analogue.
    Bałdys-Waligórska A; Krzentowska-Korek A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2011; 62(5):401-8. PubMed ID: 22069100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New medical therapies of acromegaly.
    Maffezzoni F; Frara S; Doga M; Mazziotti G; Giustina A
    Growth Horm IGF Res; 2016; 30-31():58-63. PubMed ID: 27745780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event.
    Casagrande A; Bronstein MD; Jallad RS; Moraes AB; Elias PC; Castro M; Czepielewski MA; Boschi A; Ribeiro-Oliveira A; Schweizer JR; Vilar L; Nazato DM; Gadelha MR; Abucham J;
    Neuroendocrinology; 2017; 104(3):273-279. PubMed ID: 27161443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
    Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically].
    Arao T; Okada Y; Uemura F; Nishizawa S; Tanaka Y
    J UOEH; 2017; 39(3):241-245. PubMed ID: 28904276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin analogs in acromegaly.
    Freda PU
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
    [No Abstract]   [Full Text] [Related]  

  • 39. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
    Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.